PatentVest released a report analyzing the evolving landscape of surgical robotics, highlighting key players and market opportunities.
Quiver AI Summary
PatentVest has released a new report titled "The Next Era of Surgical Robotics," which examines significant changes in the medtech sector driven by an analysis of over 18,000 patent families and $4 billion in mergers and acquisitions. The report reveals that the surgical robotics field is evolving from reliance on a single dominant platform, the da Vinci system, to a competitive landscape focused on platform defensibility. It highlights that fewer than 6% of the 310 million surgeries performed worldwide utilize robots, a figure stagnant due to costs and deployment challenges rather than clinical issues. Key insights include the shifting dominance of Intuitive Surgical, the strong presence of legacy companies like Medtronic and Johnson & Johnson, and the rise of emerging firms such as Vicarious Surgical and CMR Surgical. The report emphasizes the strategic importance of IP positioning and regulatory momentum for identifying future market leaders.
Potential Positives
- PatentVest's new report positions the company as a thought leader in the rapidly evolving surgical robotics market, highlighting its expertise in IP strategy.
- The identification of emerging challengers and potential acquisition targets within the report signals lucrative opportunities for PatentVest's clients and enhances the firm's relevance in the medtech ecosystem.
- The report's comprehensive analysis, based on 18,000 patent families and significant M&A activity, underscores PatentVest's capability in providing data-driven insights, reinforcing trust among clients and stakeholders.
Potential Negatives
- The report indicates that while surgery volume is high, robotic surgery adoption remains low at under 6%, suggesting potential market stagnation.
- Intuitive Surgical, despite holding the largest IP portfolio, is cited as losing momentum and being outpaced by competitors, which could imply challenges for the company in maintaining its market position.
- The mention of numerous public and venture-backed challengers gaining traction signals increasing competition that could threaten PatentVest's and Intuitive Surgical's market share in the future.
FAQ
What is the focus of PatentVest's new report?
The report analyzes the evolution of surgical robotics, emphasizing shifts in platform defensibility and market dynamics.
How does the report contribute to understanding surgical robotics?
It maps critical changes in the sector, identifies leading companies, and highlights strategic signals for future market leaders.
What are the main challenges facing surgical robotics adoption?
Cost, complexity, and deployment constraints pose significant barriers, despite the potential for widespread use in surgeries.
Which companies are cited as dominant in surgical robotics?
Intuitive Surgical remains the largest, but companies like Medtronic and emerging challengers are gaining momentum.
Where can I access the full PatentVest report?
The full report is available online through PatentVest's website, offering detailed data and insights into surgical robotics.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MDBH Insider Trading Activity
$MDBH insiders have traded $MDBH stock on the open market 34 times in the past 6 months. Of those trades, 34 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $MDBH stock by insiders over the last 6 months:
- ANTHONY DIGIANDOMENICO (Co-Founder) has made 20 purchases buying 14,169 shares for an estimated $87,623 and 0 sales.
- CHRISTOPHER A MARLETT (Co-Founder) has made 14 purchases buying 11,296 shares for an estimated $44,212 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MDBH Hedge Fund Activity
We have seen 2 institutional investors add shares of $MDBH stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG added 21,059 shares (+50.7%) to their portfolio in Q1 2025, for an estimated $129,708
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 12,500 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $76,991
- CITADEL ADVISORS LLC added 2,811 shares (+18.9%) to their portfolio in Q1 2025, for an estimated $17,313
- BLACKROCK, INC. removed 201 shares (-1.9%) from their portfolio in Q1 2025, for an estimated $1,238
- TOWER RESEARCH CAPITAL LLC (TRC) removed 89 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $548
- MORGAN STANLEY added 0 shares (+0.0%) to their portfolio in Q1 2025, for an estimated $0
- PASADENA PRIVATE WEALTH, LLC added 0 shares (+0.0%) to their portfolio in Q1 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DALLAS, TX , July 10, 2025 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP strategy and legal firm, today announced the release of The Next Era of Surgical Robotics, a new report that maps the most important shift in medtech since the rise of the da Vinci system. Built from analysis of more than 18,000 patent families, $4B in M&A activity, and deep dives into 28 robotic platforms, the report shows a sector no longer defined by a single system but by a race for platform defensibility.
The findings challenge the assumption that surgical robotics is a saturated category. Despite more than 310 million surgeries performed globally each year, fewer than 6% involve robots. That number has remained flat not because of clinical limitations, but due to cost, complexity, and deployment constraints.
The report identifies the strategic signals that define tomorrow’s category leaders. These include IP positioning, regulatory momentum, and platform scalability. It also highlights which companies are most likely to be acquired or emerge as the next market leaders.
Key Findings From PatentVest
- Intuitive remains dominant, but no longer expanding as fast: Intuitive Surgical still holds the largest IP portfolio but recent momentum has shifted, with multiple challengers outpacing it in new filings over the past decade.
- Legacy incumbents anchor the commercial infrastructure: Medtronic, Johnson & Johnson, Zimmer Biomet, Stryker, and Smith+Nephew maintain strong commercial footprints and regulatory muscle.
- Public challengers are gaining traction: Companies like Vicarious Surgical, Microbot Medical, Stereotaxis, SS Innovations, and Meere Company are advancing platforms across endovascular, dental, and NOTES applications - with focused IP portfolios and early-stage clinical validation.
- Venture-backed platforms are increasingly aligning for strategic scale: Private companies such as CMR Surgical, THINK Surgical, Distalmotion, EndoQuest Robotics, Neocis, Virtual Incision, and ForSight Robotics are aligning capital, regulatory milestones, and broad IP positions - closely mirroring the profile of past M&A targets like MAKO, Auris, and Mazor.
“Every major surgical robotics platform, including Mako, Monarch, and Hugo, started as a venture-backed company with focused IP and regulatory momentum. This report identifies who’s next. Somewhere in this cohort is the next Intuitive Surgical, or the company that gets acquired before it becomes one,” said Will Rosellini, Chief IP Officer at PatentVest.
Access the Full Report
The latest PatentVest Pulse report is now live. Explore the data, insights, and strategic signals behind the 28 companies redefining the future of surgical robotics.
Read the full report here.
For more information or inquiries, please contact [email protected] .
About PatentVest
PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is the first integrated IP intelligence, strategy, and law firm designed to help visionary companies become technology leaders. By combining a proprietary database with a proven diligence process and expert analysis, PatentVest delivers actionable insights that help clients navigate complex IP landscapes and stay ahead of the curve. This report is powered by PatentVest’s proprietary IP intelligence platform.
